Showing posts with label neurorehabilitation research journal. Show all posts
Showing posts with label neurorehabilitation research journal. Show all posts

Monday, 3 July 2017

The importance of early diagnosis of subdural arteriovenous fistula for clinical recovery.....


Sub dural arteriovenous fistulas (SDAVF) represent a rare disease of the spinal cord with diverse neurological complains resembling polyneuropathies of myelopathies. Due to the absence of specific clinical signs the diagnosis relies upon the MRI findings, which consists of the following classical triad of 1) dilated vessels in the subdural space, 2) central spinal cord edema and 3) contrast enhancement of the affected segments. A fourth yet inconsistent finding is an enlarged conus medullaris.

neurorehabilitation research journal
The triad is however often incomplete and in the absence of the engorged perimedullary vessels the diagnosis can remains elusive for an extensive period of time and until an advanced level of clinical disability is reached. Unlike most other immune of infectious causes of medullary dysfunction, SDAVF is a treatable condition, surgical treatment usually stopping the progression of neurological complains. Therefore, an early diagnosis is the most important factor associated with neurological recovery. The aim of this case report is to illustrate how essential a prompt diagnosis is by presenting two patients with very different clinical outcomes based on the time from the initial complains to the correct diagnosis.

Tuesday, 6 June 2017

Stroke prevention with novel oral anticoagulants in patients with nonvalvular atrial fibrillation


Stroke is a syndrome caused by the reduction or cessation of blood flow to the brain causing neurological dysfunction. While some strokes may be the result of a haemorrhage, majority (85%) are due to ischaemia. Many ischaemic events are cardioembolic, of these the majorities are due to atrial fibrillation (AF).

neurorehabilitation research journal
There are currently four novel anticoagulants (NOACs) which can be prescribed for the prophylaxis of stroke in those with non-valvular AF. These NOACs include dabigatran, a direct thrombin inhibitor, and the others, rivaroxaban, apixaban and Edoxaban are Factor-Xa inhibitors.

Vitamin K antagonist, warfarin, has certain limitations that NOACs overcome with fixed dosing regimens corrected to renal function, no necessity to regularly monitor coagulation parameters and fewer interactions with food and medications.